Sterol Composition of Clinically Relevant Mucorales and Changes Resulting from Posaconazole Treatment

Christoph Müller; Thomas Neugebauer; Patrizia Zill; Cornelia Lass-Flörl; Franz Bracher; Ulrike Binder

doi:10.3390/molecules23051218

. 2018 May 19;23(5):1218. doi: 10.3390/molecules23051218

Sterol Composition of Clinically Relevant Mucorales and Changes Resulting from Posaconazole Treatment

Christoph Müller ¹, Thomas Neugebauer ², Patrizia Zill ¹, Cornelia Lass-Flörl ², Franz Bracher ¹, Ulrike Binder ^2,^*

Editors: Wenxu Zhou, De-An Guo

PMCID: PMC6100088 PMID: 29783739

Abstract

Mucorales are fungi with increasing importance in the clinics. Infections take a rapidly progressive course resulting in high mortality rates. The ergosterol biosynthesis pathway and sterol composition are of interest, since they are targeted by currently applied antifungal drugs. Nevertheless, Mucorales often exhibit resistance to these drugs, resulting in therapeutic failure. Here, sterol patterns of six clinically relevant Mucorales (Lichtheimia corymbifera, Lichtheimia ramosa, Mucor circinelloides, Rhizomucor pusillus, Rhizopus arrhizus, and Rhizopus microsporus) were analysed in a targeted metabolomics fashion after derivatization by gas chromatography-mass spectrometry. Additionally, the effect of posaconazole (POS) treatment on the sterol pattern of R. arrhizus was evaluated. Overall, fifteen different sterols were detected with species dependent variations in the total and relative sterol amount. Sterol analysis from R. arrhizus hyphae confronted with sublethal concentrations of posaconazole revealed the accumulation of 14-methylergosta-8,24-diene-3,6-diol, which is a toxic sterol that was previously only detected in yeasts. Sterol content and composition were further compared to the well-characterized pathogenic mold Aspergillus fumigatus. This work contributes to a better understanding of the ergosterol biosynthesis pathway of Mucorales, which is essential to improve antifungal efficacy, the identification of targets for novel drug design, and to investigate the combinatorial effects of drugs targeting this pathway.

Keywords: Mucorales, Rhizopus arrhizus, sterol pattern, antifungal effectivity, gas chromatography-mass spectrometry (GC-MS), posaconazole

1. Introduction

The order Mucorales represent the most prominent order of zygospore-forming fungi, which was formerly placed in the phylum Zygomycota and was referred to as Zygomycetes. Over the years, this phylum has undergone constant taxonomic rearrangements. Now, the Mucorales, or mucormycetes, are placed in the phylum Glomeromycota and subphylum Mucormycotina [1,2,3]. Mucorales are mainly saprophytes commonly found in soil and decomposing material. Members of this group play various important roles for human life—e.g., Mucor spp., are of biotechnological importance due to their high growth rates and their great potential in the production of secondary metabolites [4]. Other Mucorales, such as Rhizopus spp., have been used for food fermentation in Asia for centuries [5]. Contrary to these positive effects of mucoralean fungi on human life, they also cause a wide range of diseases to plants, animals, and human beings. In the last ten years, the number of mucormycosis cases (also known as zygomycosis) [3,6] has increased significantly in the clinics. Mucorales that were isolated in high abundance from patient material belong to the following genera: Rhizopus, Lichtheimia (formerly Absidia), Mucor, Rhizomucor, and Cunninghamella. Worldwide, Rhizopus arrhizus is the most common species that was isolated from clinical specimen. The clinical presentation of mucormycosis varies, with mostly rhinocerebral, pulmonary and gastrointestinal manifestations. Primarily, immunocompromised patients are at risk to develop mucormycosis, but some forms, such as cutaneous mucormycosis, have also been seen in otherwise healthy persons [1,7]. The aggressive course of the disease, delayed diagnosis, and poor treatment options result in unacceptably high mortality rates (40–70%), even with antifungal therapy. Often, mucormycosis is seen as so called breakthrough infection when voriconazole is applied as prophylactic treatment regime [6]. Antifungal drugs currently licensed for treatment of mucormycosis are the polyene antifungal amphotericin B (AMB), preferably the liposomal formulation as first line treatment, and the triazole posaconazole as salvage treatment. In 2015, another azole, isavuconazole (ISA), was approved by the Food and Drug Administration (FDA) as a stand-alone treatment for mucormycosis [1,8,9,10,11,12,13]. AMB forms 1:1 adducts with fungal ergosterol and induces an accumulation of reactive oxygen species in the cytoplasm [14,15]. Azoles conduct their antifungal activity by inhibiting the enzyme sterol C14-demethylase (named ERG11 in yeasts, and CYP51 in Aspergillus spp., Figure 1, enzyme A) [16,17]. POS is also very active against Aspergillus isolates and used in the therapy of invasive aspergillosis. In contrast, another second-generation triazole, voriconazole (VRC), was shown to have no in vitro nor in vivo activity against Mucormycetes [13,15,18,19,20]. The limited arsenal of highly active anti-mucoralean drugs, plus the occurrence of AMB and azole resistant strains highlight the importance of illuminating the mode of action of antifungal drugs on, and resistance mechanisms in this group of fungi [13,15]. As the target of the currently used antifungal drugs against Mucorales is ergosterol or its biosynthesis, respectively, it is of great importance to understand the biosynthetic pathway and decipher the differences to other human pathogenic fungi.

Preferred ergosterol biosynthesis pathways in yeasts (*S. cerevisiae*) and molds (*A. fumigatus*) starting from lanosterol. Enzymes: (A) sterol C14-demethylase, (B) sterol C24-methyltransferase.

For two major human pathogenic fungi, the yeast Candida albicans, and the mold Aspergillus fumigatus, differences in the ergosterol biosynthesis pathways have already been elucidated. In Candida spp., and this is similar to baker´s yeast S. cerevisiae (Figure 1, upper panel), lanosterol is the preferred substrate for the sterol C14-demethylase (Figure 1, enzyme A), which converts lanosterol into 4,4-dimethylcholesta-8,14,24-trien-3β-ol [21,22,23,24,25]. In molds, e.g., Aspergillus fumigatus, the preferred ergosterol biosynthesis route from lanosterol starts with a methylation at C-24 by sterol C24-methyltransferase (enzyme B) in order to give eburicol, and is then followed by a demethylation at C-14 by sterol C14-demethylase to give 4,4-dimethylergosta-8,14,24(28)-trien-3β-ol [24,25,26] (Figure 1, lower panel).

In the presence of azoles, the accumulation of physiological substrates for sterol C14-demethylase and a depletion of ergosterol are observed in both yeasts and molds [16,25,27,28,29,30]. The accumulation of C14-methylated sterols (e.g., lanosterol (10) and eburicol (13)) and lower levels of ergosterol as the predominant native sterol in fungi or changes in the relative sterol composition results in alterations of the plasma membrane that impact its function and the activity of membrane-bound enzymes [31,32,33].

So far, very little is known about the ergosterol biosynthesis pathway, the sterol content, and the composition of clinically relevant Mucorales, and most studies were carried out with one species or one strain only, which makes the comparison in-between the group of Mucorales difficult [26,34,35,36,37,38,39]. Therefore, a full understanding of the ergosterol biosynthesis pathway and the sterol pattern of this group of pathogenic fungi is essential to determine the efficacy of antifungal therapy, to identify targets for novel drug design, and to investigate the combinatorial effects of drugs targeting the ergosterol biosynthesis pathway. Here, the sterol pattern and sterol content of six clinically relevant Mucorales (Rhizopus (R.) arrhizus, Rhizopus microsporus Lichtheimia (L.) corymbifera, Lichtheimia ramosa, Mucor (M.) circinelloides, and Rhizomucor (Rh.) pusillus) were analysed in a targeted metabolomics fashion by gas chromatography-mass spectrometry (GC-MS). In addition, sterols in hyphae of R. arrhizus that was confronted with sub-lethal concentrations of posaconazole were analysed and compared to untreated hyphae. R. arrhizus was chosen for this test because it represents the most abundant Mucorales species from patient material worldwide. Furthermore, the obtained data were compared to the well-studied ergosterol biosynthetic pathway of Aspergillus fumigatus [16,24,25,27,30,40,41,42,43,44,45,46].

2. Results and Discussion

2.1. Relative and Absolute Amounts of Sterol Intermediates in Mucorales

In total, 14 different sterols were detected (Table 1) in the six investigated Mucormycetes (without azole treatment), which are discussed in the order of their retention time below (Figure 2, blue chromatogram).

Table 1.

Sterol content and sterol composition of six different mucormycete species and A. fumigatus. Cultures were grown in RPMI₁₆₄₀ medium over night at 37 °C before sterol extraction. The results are presented as the average of two independent experiments, comprising 6 technical replicates in total. Sterol composition is given as the relative amount of the respective sterol (%, in bold letters) of all the sterols detected. Sterol content is expressed as µg sterol intermediate/mg biomass (dry weight). Standard deviation is given in brackets. * n.d. = not detected, ** i.t. = in traces (< 0.04 µg/mg); major sterols are indicated in red.

Compound			Relative [%] and Absolute [µg/mg] Amount of Sterols in Each Species
No.	IUPAC Name	Common Name	L. corymbifera	L. ramosa	M. circinelloides	Rh. pusillus	R. arrhizus	R. microsporus	A. fumigatus
1	ergosta-5,8,22-trien-3β-ol	Lichesterol	0.2 0.02 _{(± 0.00)}	0.4 0.07 _{± 0.02)}	0.3 0.07 _{(± 0.00)}	0.2 0.05 _{(± 0.00)}	0.8 0.07 _{(± 0.01}	0.9 0.13 _{(± 0.02}	1.2 0.12 _{(± 0.03)}
2	ergosta-5,7,22-trien-3β-ol	Ergosterol	57.5 6.45 _{(± 0.66)}	69.2 13.69 _{(± 3.76)}	65.8 12.93 _{(± 0.37)}	38.0 8.13 _{(± 0.33)}	76.3 7.07 _{(± 0.04)}	70.3 9.91 _{(± 1.85)}	95.0 9.29 _{(± 2.28)}
3	ergosta-7,22-dien-3β-ol		3.5 0.39 _{(± 0.04)}	i.t.**	n.d.*	1.9 0.41 _{(± 0.02)}	0.2 0.02 _{(± 0.01)}	0.2 0.03 _{(± 0.02)}	n.d.
4	ergosta-5,7,22,24(28)-tetraen-3β-ol		0.4 0.04 _{(± 0.00)}	0.6 0.11 _{(± 0.00)}	0.5 0.10 _{(± 0.01)}	0.3 0.06 _{(± 0.00)}	1.0 0.09_{± 0.02)}	1.2 0.17 _{(± 0.03)}	0.7 0.06 _{(± 0.01)}
5	ergosta-7,22,24(28)-trien-3β-ol		0.2 0.02 _{(± 0.01)}	0.2 0.04 _{(± 0.03)}	0.2 0.04 _{(± 0.00)}	0.2 0.03 _{(± 0.02)}	0.2 0.03 _{± 0.02)}	0.2 0.03 _{(± 0.02)}	0.2 0.02 _{(± 0.00)}
6	ergosta-5,7,24(28)-trien-3β-ol		n.d. *	7.4 1.50 _{(± 1.94)}	10.4 2.05 _{(± 0.37)}	n.d. **	2.6 0.24 _{± 0.22)}	3.3 0.46 _{(± 0.39)}	0.6 0.06 _{(± 0.01)}
7	ergosta-5,7-dien-3β-ol		28.5 3.19 _{(± 0.36)}	12.3 2.48 _{(± 0.11)}	10.6 2.07 _{(± 0.26)}	37.2 9.96 _{(± 0.07)}	10.6 0.98 _{(± 0.19)}	12.9 1.82 _{(± 0.43)}	0.3 0.03 _{(± 0.00)}
8	ergosta-7,24(28)-dien-3β-ol	Episterol	2.4 0.27 _{(± 0.04)}	1.9 0.38 _{(± 0.13)}	1.8 0.35 _{(± 0.01)}	1.4 0.29 _{(± 0.01)}	2.1 0.20 _{(± 0.13)}	2.4 0.34 _{(± 0.19)}	0.8 0.08 _{(± 0.01)}
9	ergost-7-en-3β-ol		3.7 0.41 _{(± 0.02)}	0.1 0.02 _{(± 0.03)}	i.t. **	3.0 0.64 _{(± 0.02)}	0.3 0.03 _{(± 0.02)}	0.5 0.07 _{(± 0.03)}	n.d. *
10	4,4,14-trimethylcholesta-8,24-dien-3β-ol	Lanosterol	0.3 0.03 _{(± 0.00)}	1.1 0.21 _{(± 0.24)}	1.3 0.26 _{(± 0.04)}	0.7 0.07 _{(± 0.03)}	0.7 0.07 _{(± 0.03)}	1.0 0.14 _{(± 0.05)}	0.2 0.02 _{(± 0.00)}
11	4,4-dimethylcholesta-8,24-dien-3β-ol	T-MAS	0.2 0.04 _{(± 0.00)}	0.6 0.12 _{(± 0.13)}	0.7 0.15 _{(± 0.01)}	0.6 0.13 _{(± 0.01)}	0.2 0.02 _{(± 0.00)}	0.2 0.03 _{(± 0.00)}	0.4 0.04 _{(± 0.00)}
12	4-methylergost-8-en-3β-ol		0.4 0.05 _{(± 0.00)}	0.1 0.01 _{(± 0.02)}	i.t. **	0.9 0.18 _{(± 0.00)}	0.2 0.02 _{(± 0.02)}	0.2 0.02 _{(± 0.02)}	n.d. *
13	4,4,14-trimethylergosta-8,24(28)-dien-3β-ol	Eburicol	2.0 0.22 _{(± 0.01)}	5.3 1.07 _{(± 1.33)}	7.2 1.41 _{(± 1.16)}	15.4 3.29 _{(± 0.18)}	3.7 0.34 _{(± 0.12)}	5.5 0.77 _{(± 0.15)}	n.d. *
14	4,4-dimethylergosta-8,24(28)-dien-3β-ol		0.7 0.08 _{(± 0.01)}	0.9 0.17 _{(± 0.19)}	1.1 0.21 _{(± 0.01)}	0.7 0.15 _{(± 0.00)}	0.3 0.03 _{(± 0.01)}	0.3 0.05 _{(± 0.01)}	0.6 0.06 _{(± 0.00)}
	total sterol content		100 11.22 _{(± 1.16)}	100 20.17 _{(± 7.83)}	100 19.64 _{(± 0.45)}	100 21.39 _{(± 0.61)}	100 9.26 _{(± 0.66)}	100 14.09 _{(± 2.96)}	100 9.78 _{(± 2.36)}

Open in a new tab

Representative selected ion chromatograms of untreated *R. arrhizus* samples (blue) and hyphae confronted with posaconazole (red). Hyphae were confronted with sublethal concentrations (0.5 µg/mL) for 4 h. Numbers in the diagram represent the sterol intermediates as given in Table 1. X-axis presents retention time. Selected ions for chromatogram (A) m/z 363 + 366 + 365 + 407 + 408 and selected ions for chromatogram (B) m/z 343 + 377 + 379 + 393 + 472 + 486.

Ergosta-5,8,22-trien-3β-ol (lichesterol, 1) was detected in all of the six species tested. Among the Mucormycetes, highest relative amounts of this intermediate were detected in Rhizopus spp., although these amounts were still lower than in A. fumigatus, which was included for comparison.

As expected, ergosta-5,7,22-trien-3β-ol (ergosterol, 2) was identified as the dominating sterol in all the species studied. This is in agreement with a study that was carried out with R. arrhizus [39], in which ergosterol was also identified as the sterol exhibiting highest abundance. This finding is supported by a study that was investigating the phylogenetic distribution of fungal sterols [39]. One contrary result was shown by Weete et al. [37], explaining that ergosta-7,22-dien-3β-ol (3) is the major sterol (56.0 to 59.9%) and ergosterol (2) is only the second most abundant sterol (21.1–28.4%) in R. arrhizus. Importantly, the relative content of ergosterol was highly variable between the species, ranging from 38.0% in Rh. pusillus to 76.3% in R. arrhizus. In A. fumigatus, the relative amount of ergosterol reached 95.0% of all the sterols in our experimental setup. This amount is slightly higher than what was shown by a comprehensive study of Alcazar-Fuoli et al. [24], where A. fumigatus isolates reached relative ergosterol amounts of 75.8 to 88.4%. Differences in experimental setup, like growth media and the age of the cultures used for sterol extraction, might explain these differences.

Only minor amounts of ergosta-7,22-dien-3β-ol (3) were detected in most species. Only L. corymbifera and Rh. pusillus showed little higher accumulation of 3, representing 3.5% and 1.9%, respectively, whereas this intermediate was neither detected in M. circinelloides nor in A. fumigatus.

The relative amount of ergosta-5,7,22,24(28)-tetraen-3β-ol (4) and ergosta-7,22,24(28)-trien-3β-ol (5) was very low in all of the samples (0.2–1.2%). This is in agreement with the value of 1.2% of 4 reported for M. rouxii [36].

Sterol 6, ergosta-5,7,24(28)-trien-3β-ol, was found in five out of the seven species tested (A. fumigatus included), it exhibited the third highest abundancy among all the sterols in L. ramosa (7.4%) and M. circinelloides (10.4%). Interestingly, sterol 6 was missing in L. corymbifera and Rh. pusillus.

In all Mucorales strains, significant amounts of ergosta-5,7-dien-3β-ol (7), the saturated side chain analogue of ergosterol (2) were found (10.6–37.2%), making it the second most abundant sterol after ergosterol in the Mucorales, whereas only a small amount (0.3%) of this sterol was detected in A. fumigatus. Interestingly, in Rh. pusillus the relative amount of ergosterol (2) and ergosta-5,7-dien-3β-ol (7) were nearly equal (38.0% and 37.2%), a characteristic that seems unique for this species. McCorkindale et al. [34] also detected larger amounts of 7 in Mucorales (mean 45%; n = 8) and also Weete et al. [39] identified 7 in Rhizomucor pusillus (formerly named Mucor pusillus). This indicates a putative role of ergosta-5,7-dien-3β-ol (7) as a marker sterol for the identification and classification of Mucorales species. This sterol was not found in studies evaluating sterols of A. fumigatus [24,40], while we detected minor amounts (0.3%) in our cultures. From previous studies, we learned that ergosta-5,7-dien-3β-ol (7) is only found in very little amounts in molds [25,41,42] and yeasts [25,29,43,44].

Episterol, ergosta-7,24(28)-dien-3β-ol (8), was evident in all of the samples, ranging from 1.4% (Rh. pusillus) to 2.4% in (L. corymbifera and R. microsporus). This sterol was also detected by Safe [36] in another mucoralean fungus, M. rouxii, in which the amount of free and bounded 8 was shown to be strongly dependent on the growth conditions (1.1–25.8%).

All of the Mucorales strains produced ergost-7-en-3β-ol (9) with maximum levels in L. corymbifera (3.7%) and Rh. pusillus (3.0%). In contrast to the results of Weete et al. [37] (mean 13.5%; n = 6), we detected clearly lower levels (0.3%) of 9 in R. arrhizus.

Low percentages (≤ 1.3%) of lanosterol (4,4,14-trimethylcholesta-8,24-dien-3β-ol, 10), T-MAS (4,4-dimethylcholesta-8,24-dien-3β-ol, 11), and 4-methylergost-8-en-3β-ol (12) were ubiquitously found in all of the samples.

Most interestingly, a high amount of eburicol (4,4,14-trimethylergosta-8,24(28)-dien-3β-ol, 13) was detected to a degree that is usually only observed under azole treatment in fungi [25,29,41,43]. Levels reached up to 15.4% in Rh. pusillus, all other species also showed considerably high eburicol levels, ranging from 2.0% (L. corymbifera) to 7.2% (M. circinelloides). In our experimental setup, we did not detect eburicol in A. fumigatus, which is in contrast to the sterol profile of A. fumigatus in Alcazar-Fuoli et al. [24], where an eburicol content of approx. 1.9% was reported. Different growth conditions and different growth media might explain this discrepancy.

The last detected sterol, 4,4-dimethylergosta-8,24(28)-dien-3β-ol (14), was present in all of the samples, ranging from 0.3% (R. arrhizus) to 1.1% (M. circinelloides).

Sterol 1 and the sterols 4, 6, 10–14 were not explicitly mentioned in previous reports on the sterol composition of Mucormycetes [26,34,35,36,37,38,39], but the percentages that we obtained in our study were in the range of other fungi [22,24,40,41,42].

Additional to the relative amount of sterol intermediates, we also determined the actual amount of each sterol, which was expressed as µg/mg biomass, (dry weight, Table 1). The total sterol content was proportionately 1–2% of the total mycelial biomass, which is in agreement with what has been detected for other Mucor species before [36]. Lowest amount of total sterols was found in R. arrhizus (9.26 µg/mg) and highest in Rh. pusillus (21.39 µg/mg). The values of each intermediate determined correlate with the relative amounts that were previously described. In A. fumigatus, a total sterol content of 9.78 µg/mg was determined, of which 9.25 µg/mg was ergosterol, an amount that is comparable to previously reported data [24].

2.2. Sterol Composition and Sterol Content of Posaconazole Treated R. arrhizus

To investigate the effect of the sterol C14-demethylase inhibitor POS on the sterol composition and content of Mucorales, R. arrhizus hyphae confronted with sublethal concentrations (0.5 µg/mL) of POS were compared to the sterol pattern of untreated hyphae Figure 2 and Figure 3, Table 2. For comparison and also to validate our results that were obtained with Mucorales, we included A. fumigatus, in which the effect of azole treatment on sterol pattern has been extensively studied [24,25,40,41,45].

Relative amounts [%] of the most prominent sterols in posaconazole treated (red) and untreated (blue) *R. arrhizus* hyphae. Cultures, pre-grown for 16 h, were confronted with 0.5 µg/mL posaconazole for 4 h before sterol extraction. Sterol pattern was compared to untreated controls, which were incubated under identical conditions. Error bars represent standard deviation out of two independent experiments, comprising six technical replicates. (* p < 0.05; *** p < 0.001: student’s t-test). For detailed information on all sterols extracted, see Table 2.

Table 2.

Sterol content and sterol composition of R. arrhizus and A. fumigatus confronted with sublethal concentrations of posaconazole (POS) when compared to the untreated controls. Cultures were grown in RPMI₁₆₄₀ medium over night at 37 °C before being transferred to fresh media containing 0.5 µg/mL POS, or no POS. Cultures were incubated for additional 4 h before sterol extraction. The results are presented as the average of two independent experiments, comprising six technical replicates in total. Sterol composition is given as the relative amount of the respective sterol (%, in bold letters) of all sterols detected. Sterol content is expressed as µg sterol intermediate/mg biomass (dry weight). Standard deviation is given in brackets.* n.d. = not detected, ** i.t. = in traces (< 0.04 µg/mg), major sterols are indicated in red.

Compound			Relative [%] and Absolute [µg/mg] Amount of Sterols
Compound			R. arrhizus		A. fumigatus
No.	IUPAC Name	Common Name	POS Treated	Untreated	POS Treated	Untreated
1	ergosta-5,8,22-trien-3β-ol	Lichesterol	0.7 0.09 _{(± 0.01)}	0.8 0.07_{(± 0.01)}	1.2 0.10 _{(± 0.00)}	1.2 0.12 _{(± 0.03)}
2	ergosta-5,7,22-trien-3β-ol	Ergosterol	58.5 7.52 _{(± 0.20)}	76.3 7.07_{(SD ± 0.04)}	84.1 7.41 _{(± 1.05)}	95.0 9.29 _{(± 2.28)}
3	ergosta-7,22-dien-3β-ol		0.1 0.01 _{(± 0.01)}	0.2 0.02 _{(± 0.01)}	0.1 0.01 _{(± 0.01)}	n.d. *
4	ergosta-5,7,22,24(28)-tetraen-3β-ol		0.7 0.09 _{(± 0.02)}	1.0 0.09 _{(± 0.02)}	0.8 0.07 _{(± 0.01)}	0.7 0.06 _{(± 0.01)}
5	ergosta-7,22,24(28)-trien-3β-ol		0.1 0.01 _{(± 0.00)}	0.2 0.03 _{(± 0.02)}	0.2 0.01 _{(± 0.01)}	0.2 0.02 _{(± 0.00)}
6	ergosta-5,7,24(28)-trien-3β-ol		0.9 0.12 _{(± 0.12)}	2.6 0.24 _{(± 0.22)}	0.6 0.05 _{(± 0.04)}	0.6 0.06 _{(± 0.01)}
7	ergosta-5,7-dien-3β-ol		5.1 0.66 _{(± 0.33)}	10.6 0.98 _{(± 0.19)}	1.9 0.17 _{(± 0.10)}	0.3 0.03 _{(± 0.00)}
8	ergosta-7,24(28)-dien-3β-ol	Episterol	0.8 0.10 _{(± 0.00)}	2.1 0.20 _{(± 0.13)}	1.0 0.09 _{(± 0.02)}	0.8 0.08 _{(± 0.01)}
9	ergost-7-en-3β-ol		0.1 0.01_{(± 0.01)}	0.3 0.03 _{(± 0.02)}	i.t. **	n.d. *
10	4,4,14-trimethylcholesta-8,24-dien-3β-ol	Lanosterol	2.5 0.33 _{(± 0.26)}	0.7 0.07 _{(± 0.03)}	1.3 0.12 _{(± 0.12)}	0.2 0.02 _{(± 0.00)}
11	4,4-dimethylcholesta-8,24-dien-3β-ol	T-MAS	i.t. **	0.2 0.02 _{(± 0.00)}	0.4 0.04 _{(± 0.00)}	0.4 0.04 _{(± 0.00)}
12	4-methylergost-8-en-3β-ol		0.1 0.01_{(± 0.01)}	0.2 0.02 _{(± 0.02)}	n.d. *	n.d. *
13	4,4,14-trimethylergosta-8,24(28)-dien-3β-ol	Eburicol	29.1 3.74 _{(± 1.58)}	3.7 0.34 _{(± 0.12)}	6.9 0.61 _{(± 0.80)}	n.d.*
14	4,4-dimethylergosta-8,24(28)-dien-3β-ol		i.t. **	0.3 0.03 _{(± 0.01)}	0.7 0.06 _{(± 0.02)}	0.6 0.06 _{(SD ± 0.00)}
15	14-methylergosta-8,24(28)-diene-3β,6α-diol		0.7 0.09 _{(± 0.11)}	n.d. *	n.d. *	n.d.*
	total sterol content		100 12.86 _{(± 1.30)}	100 9.26 _{(± 0.66)}	100 8.81 _{(± 0.08)}	100 9.78 _{(± 2.36)}

Open in a new tab

As expected, the relative amount of ergosterol (2) was significantly reduced by 17.8% in R. arrhizus due to POS treatment. On the other hand, eburicol (13), which is one of the substrates of the azoles’ target enzyme C14-demethylase, increased by 25.4% (Figure 3), which underlines the enzyme inhibiting properties of POS also in R. arrhizus and it further indicates that 13 is the favored substrate for sterol C14-demethylase in Mucorales (Figure 4).

Putative alternative sterol biosynthesis pathway from lanosterol in Mucorales in the presence of posaconazole. Enzymes: (A) sterol C14-demethylase, (B) sterol C24-methyltransferase, (C) sterol C4-demethylase complex, (D) sterol C5-desturase.

Surprisingly, the actual amount of ergosterol (2) relative to the biomass significantly increased in POS treated R. arrhizus hyphae (from 7.07 µg/mg to 7.52 µg/mg). Furthermore, a significant increase of the total sterol content (from 9.26 µg/mg to 12.86 µg/mg) was evident, which is most likely due to the accumulation of new sterols and the increased amount of ergosterol precursors, such as eburicol, which is increased eight-fold when compared to the untreated samples. This finding reflects what was shown by Weete and Wise [26] in propiconazole treated M. rouxii. However, this is contrary to our observations in A. fumigatus, where inhibition of sterol C14-demethylase resulted in ergosterol reduction (from 9.29 µg/mg to 7.41 µg/mg), and in this course resulted in a decrease of the total sterol content from 9.78 µg/mg to 8.81 µg/mg, although this decrease was not significant. Our results that were obtained for A. fumigatus correlate with the results of Alcazar-Fuoli et al. [27], showing that in strains with defective sterol C14-demethylase, caused by mutations in one of the two cyp51 genes, statistically lower amounts of total ergosterol were detected than in the wildtype strain.

Another sterol, ergosta-5,7-dien-3β-ol (7), was clearly reduced from 10.6% to 5.1% in R. arrhizus. In A. fumigatus, the opposite effect was observed for 7, resulting in a slight increase from 0.3% to 1.9%. Ergosta-5,7-dien-3β-ol (7) is a substrate for sterol C22-desaturase [25], the final enzyme in ergosterol biosynthesis, which converts 7 into ergosterol (2). The decrease of non-C14-methylated sterol levels under azole treatment can be explained by an up-regulation of ergosterol biosynthesis enzymes, which is aimed at converting all of the intermediates into ergosterol (e.g., 7), to avoid the impairment of membrane function. In both, R. arrhizus and A. fumigatus, a significant accumulation (relative and total amount) of lanosterol (10, Figure 1, Figure 2, Figure 3 and Figure 4) was observed. Lanosterol (10) is a further physiological substrate for the inhibited enzyme sterol C14-demethylase (Figure 1 and Figure 4), which explains the accumulation due to enzyme inhibition, even though eburciol (13) was shown to be the favored enzyme substrate in molds (Mucorales and A. fumigatus) [24,25,26,27].

Most interestingly, the non-physiological 14-methylergosta-8,24(28)-diene-3β,6α-diol (15) was found (0.7%) in POS that was treated R. arrhizus. Accumulation of this toxic intermediate [28,29,46] under the inhibition of sterol C14-demethylase was only detected in yeasts so far, but not in A. fumigatus or another filamentous fungus (Figure 4). Further studies are needed to verify if the accumulation of 14-methylergosta-8,24(28)-diene-3β,6α-diol (15) is unique for R. arrhizus or is ubiquitously found in clinically relevant Mucorales upon azole treatment.

The relative amounts of sterols 1, 3–6, 8, 9, 11, 12, 14 were not, or only to a minor extent, affected by POS treatment Table 2.

In conclusion, the azole activity in Mucorales results in significant alterations of the sterol composition, but it does not subsequently lead to a reduction of the total sterol content. The high amount of eburicol, even in untreated hyphae of the Mucorales, let us hypothesize that these fungi could be less affected by the accumulation of non-physiological intermediates due to azole treatment, which is reflected in their lower sensitivity to azole drugs when compared to other molds. In the genome of R. arrhizus two paralogous genes encoding for sterol C14-demethylase have been found [20]. It remains to be elucidated if the expression of both the genes is effected to a similar extent in the presence of azoles. So far, our results in R. arrhizus let us hypothesize that sterol C14-demethylase is only partly inhibited, as R. arrhizus is still able to synthesize ergosterol. This has been shown for other fungi as well, and it reflects that molds inherit a wide repertoire of adaption mechanisms to overcome such drawbacks. From the sterol pattern, we learn that in Mucorales the entry into the post-lanosterol pathway of ergosterol biosynthesis is similar to other molds, whereas under azole treatment, differences to molds, e.g., A. fumigatus were detected, resulting in the accumulation of a non-physiological sterol (14-methylergosta-8,24(28)-diene-3β,6α-diol, 15) which has so far only been found in azole treated yeasts (Figure 4). Because the Mucorales exhibit high variability in their susceptibility to azoles, it is of special interest to decipher the effect of azoles on sterol composition and the content of other clinically relevant mucoralean fungi.

3. Material and Methods

3.1. Fungal Strains Used in This Study

The following fungal strains, all being obtained from the strain collection of the Division of Hygiene and Medical Microbiology, Medical University Innsbruck (Innsbruck, Austria), were used for sterol analysis: Aspergillus fumigatus (ATCC46645), Lichtheimia corymbifera (CBS 109940), Lichtheimia ramosa (CBS 101.55), Mucor circinelloides (CBS 394.68), Rhizomucor pusillus (CBS 219.31), Rhizopus arrhizus (CBS 126971), and Rhizopus microsporus (CBS 102277).

3.2. Fungal Growth and Culture Conditions

All of the strains were cultivated on supplemented minimal agar (SUP) at 37 °C until sporulation (five days). Spores were obtained by harvesting them with sterile spore suspension buffer (0.9% NaCl, 0.01% Tween80). To obtain mycelia for sterol extraction, all of the strains were cultivated in RPMI₁₆₄₀ cell culture medium (Sigmaaldrich, Vienna, Austria) at 37 °C with shaking overnight. Cultures of R. arrhizus and R. microsporus with optimal growth (fine mycelia, no formation of hyphal pellets) were harvested and transferred to a new shake flask containing RPMI₁₆₄₀ plus 0.5 µg/mL posaconazole (POS). Cultures were further incubated in the presence of posaconazole for 4 h. Untreated controls were transferred into new medium without posaconazole. Then, the cultures were harvested by filtration, washed, and freeze dried to determine the fungal biomass on dry weight basis.

3.3. Sterol Extraction

Six mg of dry fungal biomass were used for sterol extraction as described by Müller et al. [25].

3.4. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis of Sterol TMS Ethers

Sterol pattern was determined by GC-MS, according to Müller et al. [25,43]. The quantification, managed with an external calibration with ergosterol, consists of six levels with concentrations up to 20 µg/mg. The base peak of each sterol TMS ether were taken as a quantifier ion for calculating the peak areas for IS cholestane m/z 217, 1 ergosta-5,8,22-trien-3β-ol (lichesterol) m/z 363, 2 ergosta-5,7,22-trien-3β-ol (ergosterol) m/z 363, 3 ergosta-7,22-dien-3β-ol m/z 343, 4 ergosta-5,8,22,24(28)-tetraen-3β-ol m/z 466, 5 ergosta-7,22,24(28)-trien-3β-ol m/z 343, 6 ergosta-5,7,24(28)-trien-3β-ol m/z 363, 7 ergosta-5,7-dien-3β-ol m/z 365, 8 ergosta-7,24(28)-dien-3β-ol (episterol) m/z 343, 9 ergost-7-en-3β-ol m/z 472, 10 4,4,14-trimethylcholesta-8,24-dien-3β-ol (lanosterol) m/z 393, 11 4,4-dimethylcholesta-8,24-dien-3β-ol (T-MAS) m/z 379, 12 4-methylergost-8-en-3β-ol m/z 486, 13 4,4,14-trimethylergosta-8,24(28)-dien-3β-ol (eburicol) m/z 407, 14 4,4-dimethylergosta-8,24(28)-dien-3β-ol m/z 408, and 15 14-methylergosta-8,24(28)-diene-3β,6α-diol m/z 377. Sterols 4,4-dimethylcholesta-8,14,24-trien-3β-ol (FF-MAS) 4,4-dimethylergosta-8,14,24(28)-trien-3β-ol, and 14-methylergosta-8,24(28)-dien-3β-ol were not detected in this study. For detailed information about these sterols, see literature [25]. Representative selected ion chromatograms of sterol fractions from R. arrhizus are given in Figure 2.

The amount of each sterol was expressed as µg per mg dry weight. The results represent the mean (µg/mg ± S.D.) of two independent biological replicates, including six technical parallels. Experiments involving POS treatment were carried out in triplicate. The sterol composition is expressed as relative amount of total sterols (%).

Acknowledgments

The authors would like to thank Denise Grässle and Verena Naschberger for excellent technical assistance. C.L.-F. has received grant support from the Austrian Science Fund (FWF), MFF Tirol, Astellas Pharma, Gilead Sciences, Pfizer, Schering Plough, and Merck Sharp & Dohme. She has been an advisor/consultant to Gilead Sciences, Merck Sharp & Dohme, Pfizer, and Schering Plough. She has received travel/accommodation expenses from Gilead Sciences, Merck Sharp & Dohme, Pfizer, Astellas, and Schering Plough and has been paid for talks on behalf of Gilead Sciences, Merck Sharp & Dohme, Pfizer, Astellas, and Schering Plough. U.B. has received an independent research grant from Gilead Sciences. All other authors have no conflicts of interest to declare.

Author Contributions

Conceptualization, C.M. and U.B.; Methodology, C.M., T.N., P.Z. and U.B.; Formal Analysis, C.M., T.N., P.Z. and U.B.; Investigation, C.M., T.N., P.Z. and U.B; Resources, F.B. and C.L.-F.; Data Curation, C.M. and U.B.; Writing-Original Draft Preparation, C.M. and U.B.; Writing-Review & Editing, C.M., F.B., C.L.-F., U.B.; Visualization, C.M. and U.B.; Supervision, F.B., U.B. and C.L.-F.; Funding Acquisition, C.L.-F.

Funding

This work was financially supported by the “Christian Doppler Forschungsgesellschaft” (CD-Labor Invasive Pilzinfektionen) to C.L.-F.

Conflicts of Interest

The authors declare no conflict of interest.

Footnotes

Sample Availability: Samples of the compounds are not available from the authors.

References

1.Spellberg B., Edwards J., Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation and management. Clin. Microbiol. Rev. 2005;18:556–569. doi: 10.1128/CMR.18.3.556-569.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Hibbett D.S., Binder M., Bischoff J.F., Blackwell M., Cannon P.F., Eriksson O.E., Huhndorf S., James T., Kirk P.M., Lücking R., et al. A higher-level phylogenetic classification of the Fungi. Mycol. Res. 2007;111:509–547. doi: 10.1016/j.mycres.2007.03.004. [DOI] [PubMed] [Google Scholar]
3.Kwon-Chung K.J. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: Molecular mycologic perspectives. Clin. Infect. Dis. 2012;54:S8–S15. doi: 10.1093/cid/cir864. [DOI] [PMC free article] [PubMed] [Google Scholar]
4.Morin-Sardin S., Nodet P., Coton E., Jany J.-L. Mucor: A Janus-faced fungal genus with human health impact and industrial applications. Fungal Biol. Rev. 2017;31:12–32. doi: 10.1016/j.fbr.2016.11.002. [DOI] [Google Scholar]
5.Dolatabadi S., Scherlach K., Figge M., Hertweck C., Dijksterhuis J., Menken S.B., de Hoog G.S. Food preparation with mucoralean fungi: A potential biosafety issue. Fungal Biol. 2016;120:393–401. doi: 10.1016/j.funbio.2015.12.001. [DOI] [PubMed] [Google Scholar]
6.Lewis R.E., Kontoyiannis D.P. Epidemiology and treatment of mucormycosis. Future Microbiol. 2013;8:1163–1175. doi: 10.2217/fmb.13.78. [DOI] [PubMed] [Google Scholar]
7.Austin C.L., Finley P.J., Mikkelson D.R., Tibbs B. Mucormycosis: A rare fungal infection in tornado victims. J. Burn Care Res. 2014;35:164–171. doi: 10.1097/BCR.0b013e318299d4bb. [DOI] [PubMed] [Google Scholar]
8.Walsh T.J., Hiemenz J.W., Seibel N.L., Perfect J.R., Horwith G., Lee L., Silber J.L., DiNubile M.J., Reboli A., Bow E., et al. Ampothericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 1998;26:1383–1396. doi: 10.1086/516353. [DOI] [PubMed] [Google Scholar]
9.Peixoto D., Gagne L.S., Hammond S.P., Gilmore E.T., Joyce A.C., Soiffer R.J., Marty F.M. Isavuconazole treatment of a patient with disseminated mucormycosis. J. Clin. Microbiol. 2014;52:1016–1019. doi: 10.1128/JCM.03176-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Cornely O.A., Arikan-Akdagli S., Dannaoui E., Groll A.H., Lagrou K., Chakrabarti A., Lanternier F., Pagano L., Skiada A., Akova M., et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin. Microbiol. Infect. 2014;20:5–26. doi: 10.1111/1469-0691.12371. [DOI] [PubMed] [Google Scholar]
11.Maurer E., Binder U., Sparber M., Lackner M., Caramalho R., Lass-Flörl C. Susceptibility profiles of amphotericin B and posaconazole against clinical relevant Mucorales species under hypoxic conditions. Antimicrob. Agents Chemother. 2015;59:1344–1346. doi: 10.1128/AAC.04424-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Marty F.M., Ostrosky-Zeichner L., Cornely O.A., Mullane K.M., Perfect J.R., Thompson G.R., Alangaden G.J., Brown J.M., Fredricks D.N., Heinz W.J., et al. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Infect. Dis. 2016;16:828–837. doi: 10.1016/S1473-3099(16)00071-2. [DOI] [PubMed] [Google Scholar]
13.McCreary E.K., Schulz L.T., Lepak A.J. Isavuconazole: Has it saved us? A pharmacotherapy review and update on clinical experience. Curr. Treat. Options Infect. Dis. 2017;9:356–370. doi: 10.1007/s40506-017-0133-9. [DOI] [Google Scholar]
14.Gray K.C., Palacios D.S., Dailey I., Endo M.M., Uno B.E., Wilcock B.C., Burke M.D. Amphotericin primarily kills yeast by simply binding ergosterol. Proc. Natl. Acad. Sci. USA. 2012;109:2234–2239. doi: 10.1073/pnas.1117280109. [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Mesa-Arango C., Trevijano-Contador N., Román E., Sánchez-Fresneda R., Casas C., Herrero E., Argüelles J.C., Pla J., Cuenca-Estrella M., Zaragoza O. The production of reactive oxygen species is a universal action mechanism of amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drugs. Antimicrob. Agents Chemother. 2014;58:6627–6638. doi: 10.1128/AAC.03570-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Munayyer H.K., Mann P.A., Chau A.S., Yarosh-Tomaine T., Greene J.R., Hare R.S., Heimark L., Palermo R.E., Loenberg D., McNicholas P.M. Posaconazole is a potent inhibitor of sterol 14α-demethylation in yeasts and molds. Antimicrob. Agents Chemother. 2004;48:3690–3696. doi: 10.1128/AAC.48.10.3690-3696.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Miceli M.H., Kauffman C.A. Isavconazole: A new broad-spectrum triazole antifungal agent. Clin. Infect. Dis. 2015;61:1558–1565. doi: 10.1093/cid/civ571. [DOI] [PubMed] [Google Scholar]
18.Alastruey-Izquierdo A., Castelli M.V., Cuesta I., Monzon A., Cuenca-Estrella M., Rodriguez-Tudela J.L. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. Antimicrob. Agents Chemother. 2009;53:1686–1689. doi: 10.1128/AAC.01467-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
19.Pagano L., Cornely O.A., Busca A., Caira M., Cesaro S., Gasbarrino C., Girmenia C., Heinz W.J., Herbrecht R., Lass-Flörl C., et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: A report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98:e127–e129. doi: 10.3324/haematol.2012.083063. [DOI] [PMC free article] [PubMed] [Google Scholar]
20.Caramalho R., Tyndall J.D.A., Monk B.C., Larentis T., Lass-Flörl C., Lackner M. Intrinsic short-tailed azole resistance in mucormycetes s due to an evolutionary conserved aminoacid substitution of the lanosterol 14α-demethylase. Sci. Rep. 2017;7:15898. doi: 10.1038/s41598-017-16123-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Fryberg M., Oehlschlager A.C., Unrau A.M. Biosynthesis of ergosterol in yeast. Evidence for multiple pathways. J. Am. Chem. Soc. 1973;95:5747–5757. doi: 10.1021/ja00798a051. [DOI] [PubMed] [Google Scholar]
22.Osumi T., Taketani S., Katsuki H., Kuhara T., Matsumoto I. Ergosterol biosynthesis in yeast: Pathways in the late stages and their variation under various conditions. J. Biochem. 1978;83:681–691. doi: 10.1093/oxfordjournals.jbchem.a131961. [DOI] [PubMed] [Google Scholar]
23.Parks L.P. Physiological implications of sterol biosynthesis in yeast. Annu. Rev. Microbiol. 1995;49:95–116. doi: 10.1146/annurev.mi.49.100195.000523. [DOI] [PubMed] [Google Scholar]
24.Alcazar-Fuoli L., Mellado E., Garcia-Effron G., Lopez J.F., Grimalt O.J., Cuenca-Estrella J.M., Rodriguez-Tudela J.L. Ergosterol biosynthesis pathway in Aspergillus fumigatus. Steroids. 2008;73:339–347. doi: 10.1016/j.steroids.2007.11.005. [DOI] [PubMed] [Google Scholar]
25.Müller C., Binder U., Bracher F., Giera M. Antifungal drug testing: Combining minimal inhibitory concentration testing with target identification by the use of gas chromatography—Mass spectrometry. Nat. Protoc. 2017;12:947–963. doi: 10.1038/nprot.2017.005. [DOI] [PubMed] [Google Scholar]
26.Weete J.D., Wise M.L. Effects of triazoles on fungi. Exp. Mycol. 1987;11:214–222. doi: 10.1016/0147-5975(87)90007-7. [DOI] [Google Scholar]
27.Alcazar-Fuoli L., Mellado E. Ergosterol biosynthesis in Aspergillus fumigatus: Its relevance as an antifungal target and role in antifungal drug resistance. Front. Microbiol. 2013;3:1–5. doi: 10.3389/fmicb.2012.00439. [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Martel C.M., Parker J.E., Bader O., Weig M., Warrilow A.G.S., Kelly D.E., Kelly S.L. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14α-demethylase) and ERG5 (encoding C22-desturase) is cross resistant to azoles and amphotericin B. Antimicrob. Agents Chemother. 2010;54:3578–3583. doi: 10.1128/AAC.00303-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
29.Keller P., Müller C., Engelhardt I., Hiller E., Lemuth K., Eickhoff H., Wiesmüller K.H., Burger-Kentischer A., Bracher F., Rupp S. An antifungal benzimidazole derivative inhibits ergosterol biosynthesis and reveals novel sterols. Antimicrob. Agents Chemother. 2015;59:6296–6307. doi: 10.1128/AAC.00640-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
30.Colley T., Alanio A., Kelly S.L., Sehra G., Kizawa Y., Warilow A.G.S., Parker J.E., Kelly D.E., Kimura G., Anderson-Dring L., et al. In vitro and in vivo antifungal profile of a novel and long acting inhaled azole PC945, on Aspergillus fumigatus infection. Antimicrob. Agents Chemother. 2017;61:1–14. doi: 10.1128/AAC.02280-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
31.Georgopapadakou N.H. Antifungals: Mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbiol. 1998;1:547–557. doi: 10.1016/S1369-5274(98)80087-8. [DOI] [PubMed] [Google Scholar]
32.Ghannoum M.A., Rice L.B. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 1999;12:501–517. doi: 10.1128/cmr.12.4.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
33.Lupetti A., Danesi R., Campa M., del Tacca M., Kelly S. Molecular basis of resistance to azole antifungals. Trends Mol. Med. 2002;8:76–81. doi: 10.1016/S1471-4914(02)02280-3. [DOI] [PubMed] [Google Scholar]
34.McCorkindale N.J., Hutchinson S.A., Pursey B.A., Scott W.T., Wheeler R. A comparison of the types of sterol found in species of the Saprolegniales and Leptomitales with those found in some other Phycomycetes. Phytochemistry. 1969;8:861–867. doi: 10.1016/S0031-9422(00)85874-4. [DOI] [Google Scholar]
35.Gordon P.A., Stewart P.R., Clark-Walker G.D. Fatty acids and sterol composition of Mucor genevensis in relation to dimorphism and anaerobic growth. J. Bacteriol. 1971;107:114–120. doi: 10.1128/jb.107.1.114-120.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
36.Safe S. The effect of environment on the free and hydrosoluble sterols of Mucor rouxii. Biochim. Biophys. Acta. 1973;326:471–475. doi: 10.1016/0005-2760(73)90147-1. [DOI] [PubMed] [Google Scholar]
37.Weete J.D., Lawler G.C., Laseter J.L. Total lipid and sterol components of Rhizopus arrhizus: Identification and metabolism. Arch. Biochem. Biophys. 1973;155:411–419. doi: 10.1016/0003-9861(73)90131-8. [DOI] [PubMed] [Google Scholar]
38.Weete J.D., Gandhi S.R. Sterols of the phylum Zygomycota: Pylogenetic implications. Lipids. 1997;32:1309–1316. doi: 10.1007/s11745-006-0169-y. [DOI] [PubMed] [Google Scholar]
39.Weete J.D., Abril M., Blackwell M. Phylogenetic distribution of fungal sterols. PLoS ONE. 2010;5:e10899. doi: 10.1371/journal.pone.0010899. [DOI] [PMC free article] [PubMed] [Google Scholar]
40.Dannaoui E., Persat F., Borel E., Piens M.-A., Picot S. Sterol composition of itraconazole-resistant and itraconazole-susceptible isolates of Aspergillus fumigatus. Can. J. Microbiol. 2001;47:706–710. doi: 10.1139/w01-066. [DOI] [PubMed] [Google Scholar]
41.Gsaller F., Hortschansky P., Furukawa T., Carr P.D., Rash B., Capilla J., Müller C., Bracher F., Bowyer P., Haas H., et al. Sterol biosynthesis and azole tolerance is governed by the opposing actions of SrbA and the CCAAT binding complex. PloS Pathog. 2016;12:e1005775. doi: 10.1371/journal.ppat.1005775. [DOI] [PMC free article] [PubMed] [Google Scholar]
42.Misslinger M., Gsaller F., Hortschansky P., Müller C., Bracher F., Bromley M.J., Haas H. The cytochrome b5 CybE is regulated by iron availability and is crucial for azole resistance in A. fumigatus. Metallomics. 2017;9:1655–1665. doi: 10.1039/C7MT00110J. [DOI] [PubMed] [Google Scholar]
43.Müller C., Staudacher V., Krauss J., Giera M., Bracher F. A convenient cellular assay for the identification of the molecular target of ergosterol biosynthesis inhibitors and quantification of their effects on total ergosterol biosynthesis. Steroids. 2013;78:483–493. doi: 10.1016/j.steroids.2013.02.006. [DOI] [PubMed] [Google Scholar]
44.Müller C., Binder U., Maurer E., Grimm C., Giera M., Bracher F. Fungal sterol C22-desaturase is not an antimycotic target as shown by selective inhibitors and testing on clinical isolates. Steroids. 2015;101:1–6. doi: 10.1016/j.steroids.2015.05.004. [DOI] [PubMed] [Google Scholar]
45.Nemec T., Jernejec K., Cimerman A. Sterols and fatty acids of different Aspergillus species. FEMS Microbiol. Lett. 1997;149:201–205. doi: 10.1111/j.1574-6968.1997.tb10329.x. [DOI] [Google Scholar]
46.Kelly S.L., Lamb D.C., Corran A.J., Baldwin B.C., Kelly D.E. Mode of action and resistance to azole antifungals associated with the formation of 14α-methylergosta-8,24(28)-dien-3β,6α-diol. Biochem. Biohys. Res. Commun. 1995;207:910–915. doi: 10.1006/bbrc.1995.1272. [DOI] [PubMed] [Google Scholar]

[B1-molecules-23-01218] 1.Spellberg B., Edwards J., Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation and management. Clin. Microbiol. Rev. 2005;18:556–569. doi: 10.1128/CMR.18.3.556-569.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B2-molecules-23-01218] 2.Hibbett D.S., Binder M., Bischoff J.F., Blackwell M., Cannon P.F., Eriksson O.E., Huhndorf S., James T., Kirk P.M., Lücking R., et al. A higher-level phylogenetic classification of the Fungi. Mycol. Res. 2007;111:509–547. doi: 10.1016/j.mycres.2007.03.004. [DOI] [PubMed] [Google Scholar]

[B3-molecules-23-01218] 3.Kwon-Chung K.J. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: Molecular mycologic perspectives. Clin. Infect. Dis. 2012;54:S8–S15. doi: 10.1093/cid/cir864. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B4-molecules-23-01218] 4.Morin-Sardin S., Nodet P., Coton E., Jany J.-L. Mucor: A Janus-faced fungal genus with human health impact and industrial applications. Fungal Biol. Rev. 2017;31:12–32. doi: 10.1016/j.fbr.2016.11.002. [DOI] [Google Scholar]

[B5-molecules-23-01218] 5.Dolatabadi S., Scherlach K., Figge M., Hertweck C., Dijksterhuis J., Menken S.B., de Hoog G.S. Food preparation with mucoralean fungi: A potential biosafety issue. Fungal Biol. 2016;120:393–401. doi: 10.1016/j.funbio.2015.12.001. [DOI] [PubMed] [Google Scholar]

[B6-molecules-23-01218] 6.Lewis R.E., Kontoyiannis D.P. Epidemiology and treatment of mucormycosis. Future Microbiol. 2013;8:1163–1175. doi: 10.2217/fmb.13.78. [DOI] [PubMed] [Google Scholar]

[B7-molecules-23-01218] 7.Austin C.L., Finley P.J., Mikkelson D.R., Tibbs B. Mucormycosis: A rare fungal infection in tornado victims. J. Burn Care Res. 2014;35:164–171. doi: 10.1097/BCR.0b013e318299d4bb. [DOI] [PubMed] [Google Scholar]

[B8-molecules-23-01218] 8.Walsh T.J., Hiemenz J.W., Seibel N.L., Perfect J.R., Horwith G., Lee L., Silber J.L., DiNubile M.J., Reboli A., Bow E., et al. Ampothericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 1998;26:1383–1396. doi: 10.1086/516353. [DOI] [PubMed] [Google Scholar]

[B9-molecules-23-01218] 9.Peixoto D., Gagne L.S., Hammond S.P., Gilmore E.T., Joyce A.C., Soiffer R.J., Marty F.M. Isavuconazole treatment of a patient with disseminated mucormycosis. J. Clin. Microbiol. 2014;52:1016–1019. doi: 10.1128/JCM.03176-13. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B10-molecules-23-01218] 10.Cornely O.A., Arikan-Akdagli S., Dannaoui E., Groll A.H., Lagrou K., Chakrabarti A., Lanternier F., Pagano L., Skiada A., Akova M., et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin. Microbiol. Infect. 2014;20:5–26. doi: 10.1111/1469-0691.12371. [DOI] [PubMed] [Google Scholar]

[B11-molecules-23-01218] 11.Maurer E., Binder U., Sparber M., Lackner M., Caramalho R., Lass-Flörl C. Susceptibility profiles of amphotericin B and posaconazole against clinical relevant Mucorales species under hypoxic conditions. Antimicrob. Agents Chemother. 2015;59:1344–1346. doi: 10.1128/AAC.04424-14. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B12-molecules-23-01218] 12.Marty F.M., Ostrosky-Zeichner L., Cornely O.A., Mullane K.M., Perfect J.R., Thompson G.R., Alangaden G.J., Brown J.M., Fredricks D.N., Heinz W.J., et al. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Infect. Dis. 2016;16:828–837. doi: 10.1016/S1473-3099(16)00071-2. [DOI] [PubMed] [Google Scholar]

[B13-molecules-23-01218] 13.McCreary E.K., Schulz L.T., Lepak A.J. Isavuconazole: Has it saved us? A pharmacotherapy review and update on clinical experience. Curr. Treat. Options Infect. Dis. 2017;9:356–370. doi: 10.1007/s40506-017-0133-9. [DOI] [Google Scholar]

[B14-molecules-23-01218] 14.Gray K.C., Palacios D.S., Dailey I., Endo M.M., Uno B.E., Wilcock B.C., Burke M.D. Amphotericin primarily kills yeast by simply binding ergosterol. Proc. Natl. Acad. Sci. USA. 2012;109:2234–2239. doi: 10.1073/pnas.1117280109. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B15-molecules-23-01218] 15.Mesa-Arango C., Trevijano-Contador N., Román E., Sánchez-Fresneda R., Casas C., Herrero E., Argüelles J.C., Pla J., Cuenca-Estrella M., Zaragoza O. The production of reactive oxygen species is a universal action mechanism of amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drugs. Antimicrob. Agents Chemother. 2014;58:6627–6638. doi: 10.1128/AAC.03570-14. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B16-molecules-23-01218] 16.Munayyer H.K., Mann P.A., Chau A.S., Yarosh-Tomaine T., Greene J.R., Hare R.S., Heimark L., Palermo R.E., Loenberg D., McNicholas P.M. Posaconazole is a potent inhibitor of sterol 14α-demethylation in yeasts and molds. Antimicrob. Agents Chemother. 2004;48:3690–3696. doi: 10.1128/AAC.48.10.3690-3696.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B17-molecules-23-01218] 17.Miceli M.H., Kauffman C.A. Isavconazole: A new broad-spectrum triazole antifungal agent. Clin. Infect. Dis. 2015;61:1558–1565. doi: 10.1093/cid/civ571. [DOI] [PubMed] [Google Scholar]

[B18-molecules-23-01218] 18.Alastruey-Izquierdo A., Castelli M.V., Cuesta I., Monzon A., Cuenca-Estrella M., Rodriguez-Tudela J.L. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. Antimicrob. Agents Chemother. 2009;53:1686–1689. doi: 10.1128/AAC.01467-08. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B19-molecules-23-01218] 19.Pagano L., Cornely O.A., Busca A., Caira M., Cesaro S., Gasbarrino C., Girmenia C., Heinz W.J., Herbrecht R., Lass-Flörl C., et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: A report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98:e127–e129. doi: 10.3324/haematol.2012.083063. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B20-molecules-23-01218] 20.Caramalho R., Tyndall J.D.A., Monk B.C., Larentis T., Lass-Flörl C., Lackner M. Intrinsic short-tailed azole resistance in mucormycetes s due to an evolutionary conserved aminoacid substitution of the lanosterol 14α-demethylase. Sci. Rep. 2017;7:15898. doi: 10.1038/s41598-017-16123-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B21-molecules-23-01218] 21.Fryberg M., Oehlschlager A.C., Unrau A.M. Biosynthesis of ergosterol in yeast. Evidence for multiple pathways. J. Am. Chem. Soc. 1973;95:5747–5757. doi: 10.1021/ja00798a051. [DOI] [PubMed] [Google Scholar]

[B22-molecules-23-01218] 22.Osumi T., Taketani S., Katsuki H., Kuhara T., Matsumoto I. Ergosterol biosynthesis in yeast: Pathways in the late stages and their variation under various conditions. J. Biochem. 1978;83:681–691. doi: 10.1093/oxfordjournals.jbchem.a131961. [DOI] [PubMed] [Google Scholar]

[B23-molecules-23-01218] 23.Parks L.P. Physiological implications of sterol biosynthesis in yeast. Annu. Rev. Microbiol. 1995;49:95–116. doi: 10.1146/annurev.mi.49.100195.000523. [DOI] [PubMed] [Google Scholar]

[B24-molecules-23-01218] 24.Alcazar-Fuoli L., Mellado E., Garcia-Effron G., Lopez J.F., Grimalt O.J., Cuenca-Estrella J.M., Rodriguez-Tudela J.L. Ergosterol biosynthesis pathway in Aspergillus fumigatus. Steroids. 2008;73:339–347. doi: 10.1016/j.steroids.2007.11.005. [DOI] [PubMed] [Google Scholar]

[B25-molecules-23-01218] 25.Müller C., Binder U., Bracher F., Giera M. Antifungal drug testing: Combining minimal inhibitory concentration testing with target identification by the use of gas chromatography—Mass spectrometry. Nat. Protoc. 2017;12:947–963. doi: 10.1038/nprot.2017.005. [DOI] [PubMed] [Google Scholar]

[B26-molecules-23-01218] 26.Weete J.D., Wise M.L. Effects of triazoles on fungi. Exp. Mycol. 1987;11:214–222. doi: 10.1016/0147-5975(87)90007-7. [DOI] [Google Scholar]

[B27-molecules-23-01218] 27.Alcazar-Fuoli L., Mellado E. Ergosterol biosynthesis in Aspergillus fumigatus: Its relevance as an antifungal target and role in antifungal drug resistance. Front. Microbiol. 2013;3:1–5. doi: 10.3389/fmicb.2012.00439. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B28-molecules-23-01218] 28.Martel C.M., Parker J.E., Bader O., Weig M., Warrilow A.G.S., Kelly D.E., Kelly S.L. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14α-demethylase) and ERG5 (encoding C22-desturase) is cross resistant to azoles and amphotericin B. Antimicrob. Agents Chemother. 2010;54:3578–3583. doi: 10.1128/AAC.00303-10. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B29-molecules-23-01218] 29.Keller P., Müller C., Engelhardt I., Hiller E., Lemuth K., Eickhoff H., Wiesmüller K.H., Burger-Kentischer A., Bracher F., Rupp S. An antifungal benzimidazole derivative inhibits ergosterol biosynthesis and reveals novel sterols. Antimicrob. Agents Chemother. 2015;59:6296–6307. doi: 10.1128/AAC.00640-15. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B30-molecules-23-01218] 30.Colley T., Alanio A., Kelly S.L., Sehra G., Kizawa Y., Warilow A.G.S., Parker J.E., Kelly D.E., Kimura G., Anderson-Dring L., et al. In vitro and in vivo antifungal profile of a novel and long acting inhaled azole PC945, on Aspergillus fumigatus infection. Antimicrob. Agents Chemother. 2017;61:1–14. doi: 10.1128/AAC.02280-16. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B31-molecules-23-01218] 31.Georgopapadakou N.H. Antifungals: Mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbiol. 1998;1:547–557. doi: 10.1016/S1369-5274(98)80087-8. [DOI] [PubMed] [Google Scholar]

[B32-molecules-23-01218] 32.Ghannoum M.A., Rice L.B. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 1999;12:501–517. doi: 10.1128/cmr.12.4.501. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B33-molecules-23-01218] 33.Lupetti A., Danesi R., Campa M., del Tacca M., Kelly S. Molecular basis of resistance to azole antifungals. Trends Mol. Med. 2002;8:76–81. doi: 10.1016/S1471-4914(02)02280-3. [DOI] [PubMed] [Google Scholar]

[B34-molecules-23-01218] 34.McCorkindale N.J., Hutchinson S.A., Pursey B.A., Scott W.T., Wheeler R. A comparison of the types of sterol found in species of the Saprolegniales and Leptomitales with those found in some other Phycomycetes. Phytochemistry. 1969;8:861–867. doi: 10.1016/S0031-9422(00)85874-4. [DOI] [Google Scholar]

[B35-molecules-23-01218] 35.Gordon P.A., Stewart P.R., Clark-Walker G.D. Fatty acids and sterol composition of Mucor genevensis in relation to dimorphism and anaerobic growth. J. Bacteriol. 1971;107:114–120. doi: 10.1128/jb.107.1.114-120.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B36-molecules-23-01218] 36.Safe S. The effect of environment on the free and hydrosoluble sterols of Mucor rouxii. Biochim. Biophys. Acta. 1973;326:471–475. doi: 10.1016/0005-2760(73)90147-1. [DOI] [PubMed] [Google Scholar]

[B37-molecules-23-01218] 37.Weete J.D., Lawler G.C., Laseter J.L. Total lipid and sterol components of Rhizopus arrhizus: Identification and metabolism. Arch. Biochem. Biophys. 1973;155:411–419. doi: 10.1016/0003-9861(73)90131-8. [DOI] [PubMed] [Google Scholar]

[B38-molecules-23-01218] 38.Weete J.D., Gandhi S.R. Sterols of the phylum Zygomycota: Pylogenetic implications. Lipids. 1997;32:1309–1316. doi: 10.1007/s11745-006-0169-y. [DOI] [PubMed] [Google Scholar]

[B39-molecules-23-01218] 39.Weete J.D., Abril M., Blackwell M. Phylogenetic distribution of fungal sterols. PLoS ONE. 2010;5:e10899. doi: 10.1371/journal.pone.0010899. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B40-molecules-23-01218] 40.Dannaoui E., Persat F., Borel E., Piens M.-A., Picot S. Sterol composition of itraconazole-resistant and itraconazole-susceptible isolates of Aspergillus fumigatus. Can. J. Microbiol. 2001;47:706–710. doi: 10.1139/w01-066. [DOI] [PubMed] [Google Scholar]

[B41-molecules-23-01218] 41.Gsaller F., Hortschansky P., Furukawa T., Carr P.D., Rash B., Capilla J., Müller C., Bracher F., Bowyer P., Haas H., et al. Sterol biosynthesis and azole tolerance is governed by the opposing actions of SrbA and the CCAAT binding complex. PloS Pathog. 2016;12:e1005775. doi: 10.1371/journal.ppat.1005775. [DOI] [PMC free article] [PubMed] [Google Scholar]

[B42-molecules-23-01218] 42.Misslinger M., Gsaller F., Hortschansky P., Müller C., Bracher F., Bromley M.J., Haas H. The cytochrome b5 CybE is regulated by iron availability and is crucial for azole resistance in A. fumigatus. Metallomics. 2017;9:1655–1665. doi: 10.1039/C7MT00110J. [DOI] [PubMed] [Google Scholar]

[B43-molecules-23-01218] 43.Müller C., Staudacher V., Krauss J., Giera M., Bracher F. A convenient cellular assay for the identification of the molecular target of ergosterol biosynthesis inhibitors and quantification of their effects on total ergosterol biosynthesis. Steroids. 2013;78:483–493. doi: 10.1016/j.steroids.2013.02.006. [DOI] [PubMed] [Google Scholar]

[B44-molecules-23-01218] 44.Müller C., Binder U., Maurer E., Grimm C., Giera M., Bracher F. Fungal sterol C22-desaturase is not an antimycotic target as shown by selective inhibitors and testing on clinical isolates. Steroids. 2015;101:1–6. doi: 10.1016/j.steroids.2015.05.004. [DOI] [PubMed] [Google Scholar]

[B45-molecules-23-01218] 45.Nemec T., Jernejec K., Cimerman A. Sterols and fatty acids of different Aspergillus species. FEMS Microbiol. Lett. 1997;149:201–205. doi: 10.1111/j.1574-6968.1997.tb10329.x. [DOI] [Google Scholar]

[B46-molecules-23-01218] 46.Kelly S.L., Lamb D.C., Corran A.J., Baldwin B.C., Kelly D.E. Mode of action and resistance to azole antifungals associated with the formation of 14α-methylergosta-8,24(28)-dien-3β,6α-diol. Biochem. Biohys. Res. Commun. 1995;207:910–915. doi: 10.1006/bbrc.1995.1272. [DOI] [PubMed] [Google Scholar]

PERMALINK

Sterol Composition of Clinically Relevant Mucorales and Changes Resulting from Posaconazole Treatment

Christoph Müller

Thomas Neugebauer

Patrizia Zill

Cornelia Lass-Flörl

Franz Bracher

Ulrike Binder

Roles

Abstract

1. Introduction

Figure 1.

2. Results and Discussion